See other companies on Welcome to the Jungle
Atomic AI
Drug discovery company
- 1-20 employees
- Healthcare
- B2B
- Artificial Intelligence
- Biology
- SaaS
- Science
- Oyster Point, South San Francisco, CA
Jump to section
Company mission
To unleash the power of artificial intelligence on molecular structure to engineer RNA biology, creating medicines that can tackle diseases that were previously untreatable.
Our take
Atomic AI is a biotechnology company that combines machine learning with structural biology to unlock RNA drug discovery.
The company is creating an entirely new field of drug discovery. It is developing tools that can accurately predict 3D RNA structures, essentially creating effective and safer small molecules against undruggable disease.
The company launched recently with a round of series A funding that is to be invested into accelerating growth, expanding operations and its business reach. Its attempts to revolutionise an industry is an exciting one when considering its early support.
Freddie
Company Specialist at Welcome to the Jungle
Company values
- We care about each other and our mission
- We communicate frequently and earnestly
- We are all fundamentally equal
- We push ourselves out of our comfort zone to pursue bold ideas
- We take responsibility for getting things done
- We are happy to be proven wrong
Funding (2 rounds)
Jan 2023
$35m
SERIES A
Jan 2021
$7m
SEED
Total funding: $42m
This company has top investors
Leadership
Raphael Townshend
(CEO)Obtained a PhD in Computer Science from Stanford University. Previously underwent Internships for DeepMind, Scaled Inference, and Google.